Printer Friendly

DR. CHARLES P. COX JOINS ATRIX LABORATORIES AS VICE PRESIDENT OF PRODUCT DEVELOPMENT

 DR. CHARLES P. COX JOINS ATRIX LABORATORIES
 AS VICE PRESIDENT OF PRODUCT DEVELOPMENT
 FORT COLLINS, Colo., Sept. 8 /PRNewswire/ -- Atrix Laboratories, Inc. (NASDAQ: ATRX) today announced the appointment of Charles P. Cox, Ph.D. as vice president of Product Development. Dr. Cox joins Atrix from G.D. Searle and Company where he spent four years as project director of Project Planning and Management. In this capacity, Dr. Cox oversaw the collective product development efforts of the functional disciplinary areas for the submission of NDA's and IND's. Prior to this assignment, he was a research scientist for the Molecular and Cellular Biology division at Searle. Before beginning his career at G.D. Searle and Company, Dr. Cox was a research specialist for the Health Science department at the Veteran's Administration Medical Center, as well as Assistant Professor of Medicine Research at the University of Oklahoma College of Medicine. Dr. Cox received his doctorate in Medical Microbiology and Immunology from the University of Oklahoma.
 Dr. G. Lee Southard, president and CEO of Atrix commented, "Charles Cox brings front line management experience in product development to our drug delivery and medical device programs. He is responsible for the associated manufacturing scale-up, quality assurance and the microbiological analytical support functions at Atrix, for the successful submission of IND's and NDA's for our drug products and IDE's and PMA's for medical device products. Dr. Richard Dunn, who has managed both the research and development areas, will now take the new title of vice president of Drug Delivery Research and will focus more on the drug delivery and medical device applications for the ATRIGEL (TM) system. All of us at Atrix are very pleased to have Dr. Cox on board."
 Atrix Laboratories is a drug delivery company with the ATRIGEL system, a unique, proprietary drug delivery technology that is biodegradable and can be utilized for a broad range of human and animal applications, including the treatment of periodontal disease.
 -0- 9/8/92
 /CONTACT: Dr. G. Lee Southard, president & CEO of Atrix Laboratories, Inc., 303-482-5868, or Susan Sherman of Cameron Associates, 212-644-9560, for Atrix Laboratories, Inc./
 (ATRX) CO: Atrix Laboratories, Inc. ST: Colorado IN: MTC SU: PER


AH-S -- NY003 -- 6795 09/08/92 08:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 8, 1992
Words:370
Previous Article:BIG BOY BRINGS PRESIDENTIAL CAMPAIGN TO CINCINNATI
Next Article:CAERE CORPORATION SHIPS FAXMASTER; EARLY ADOPTERS AND DISTRIBUTORS PRAISE EASE-OF-USE AND COMPLETE FUNCTIONALITY
Topics:


Related Articles
DR. D. WALTER COHEN JOINS ATRIX LABORATORIES BOARD OF DIRECTORS
ATRIX LABORATORIES ANNOUNCES SECOND QUARTER AND SIX MONTH RESULTS
ATRIX LABORATORIES AND COLGATE PALMOLIVE TO END MARKETING AGREEMENT
ATRIX ANNOUNCES PROMOTION OF MS. ELAINE GAZDECK TO V.P. OF REGULATORY AFFAIRS/QUALITY ASSURANCE
Atrix Laboratories Reports 1997 First Quarter Results
Atrix Laboratories Acquires ViroTex; Gains Four Short-Acting Drug Delivery Technologies.
Atrix Initiates Legal Action Against Block Drug Company.
Atrix patent extends patent protection on prostate cancer product.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters